Scholar Rock Holding Corp
Scholar Rock Holding Corp (SRRK): 8 pipeline candidates · 3 upcoming catalysts · ~18 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
17.9 months
D/E 0.94 · 7% dilution
Lead: Phase 2
8 candidates
3 upcoming, next in ~44d
0 buys · 22 sells (180d)
A transparent, data-derived signal for Scholar Rock Holding Corpacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$5.6B
Cash
$434.4M
Quarterly Burn
$82.1M
Runway
17.9 mo
Revenue
$0
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| Additional discovery and early preclinical programs | Preclinical |
| apitegromab | Phase 2 |
| Nusinersen | Phase 2 |
| Risdiplam | Phase 2 |
| SRK-181 | Phase 2 |
| SRK-256 | Preclinical |
| SRK-373 | Phase 1 |
| SRK-439 | Phase 1 |
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
278
Total value held
$5.50B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 17,243,152 | $847.7M |
| vanguard capital management llc | 7,782,694 | $382.6M |
| blackrock, inc. | 7,469,293 | $367.2M |
| samsara biocapital, llc | 6,897,652 | $339.1M |
| wellington management group llp | 6,717,655 | $330.2M |
| janus henderson group plc | 4,473,674 | $219.8M |
| state street corp | 4,031,317 | $198.2M |
| bellevue group ag | 3,584,573 | $176.2M |
| jennison associates llc | 3,340,492 | $164.2M |
| woodline partners lp | 3,000,940 | $147.5M |
Showing top 10 of 278 institutional holders of Scholar Rock Holding Corp. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Scholar Rock Holding Corp's pipeline?
Scholar Rock Holding Corp (SRRK) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Scholar Rock Holding Corp's lead drug candidate?
Scholar Rock Holding Corp's most advanced tracked candidate is Additional discovery and early preclinical programs (Preclinical) for Selective modulation of growth factor signaling (discovery and early preclinical programs)..
What is Scholar Rock Holding Corp's next catalyst?
Scholar Rock Holding Corp's next tracked catalyst is a Phase2_Start event — "Phase 2 Start: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 52-Week Study Evaluating the E" — expected August 1, 2026.
What is Scholar Rock Holding Corp's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Scholar Rock Holding Corp has approximately 17.9 months of cash runway.
What is Scholar Rock Holding Corp's market capitalization?
Scholar Rock Holding Corp's market capitalization is approximately $5.6B.
Get the full picture on Scholar Rock Holding Corp
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.